As accumulating evidence has consistently indicated the clinical relevance of composite use and titration of HF medications [9,10], current guidelines encourage, at a high level of recommendation, prioritizing the initiation and early titration of four types of HF agents: renin–angiotensin system inhibitors (RASis) = ACEis/ARBs/ARNis, BBs, MRAs, and SGLT2is [11,12,13]. Here, REN is linked to hydrops fetalis.